Researchers at Weill Cornell Medicine have used artificial intelligence to identify drug targets based on mapping regulatory networks in patient tumors. The study, published in Cell Systems, experimentally identified and validated four drug candidates for neuroendocrine, liver and renal cancers, which have a dismal prognosis with current therapeutic options.
Medical Xpress – latest medical and health news stories
